esmo 2017 hypersensitivity esmo 2017 hypersensitivity
E. Restuccia: Financial Interests, Personal, Full or part-time Employment: F. Hoffmann-La Roche Ltd.; Financial Interests, Personal, Stocks/Shares: Genentech, Inc; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. S. Loibl: Financial Interests, Institutional, Advisory Board: AstraZeneca; Financial Interests, Institutional, Advisory Board: AbbVie; Financial Interests, Institutional, Advisory Board: Amgen; Financial Interests, Institutional, Advisory Board: Celgene; Financial Interests, Institutional, Advisory Board: Novartis; Financial Interests, Institutional, Advisory Board: Pfizer; Financial Interests, Institutional, Advisory Board: Roche; Financial Interests, Institutional, Advisory Board: Seattle Genetics; Financial Interests, Institutional, Advisory Board: PriME/ Medscape; Financial Interests, Personal, Invited Speaker: Chugai; Financial Interests, Personal, Research Grant: Teva; Financial Interests, Personal, Research Grant: Vifor; Financial Interests, Institutional, Research Grant: Daiichi-Sankyo; Financial Interests, Institutional, Advisory Board: Lilly; Financial Interests, Institutional, Advisory Board: Samsung; Financial Interests, Institutional, Advisory Board: Eirgenix; Financial Interests, Institutional, Advisory Board: BMS; Financial Interests, Institutional, Advisory Board: Puma; Financial Interests, Personal, Research Grant: Immunomedics; Non-Financial Interests, Personal, Other, Patent EP14153692 .0 pending: Roche; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd.; Financial Interests, Institutional, Advisory Board: MSD. The median patient age was 56 years (range 1694 years). B., Phillips, P. C., Kang, T. I., et al. 24, 2432. These differences were likely related to the fact that patients with advanced disease, serous carcinoma, and ascetic malignant cells required significantly more carboplatin treatment cycles and higher carboplatin doses. Doxorubicin/adriamycin and other chemotherapies present with sudden onset hypo or hypertension in up to 60% of patients and rituximab and other monoclonal antibodies present with cutaneous and cardiovascular symptoms in 70% of the patients. The ESMOClinical Practice Guidelines(CPGs) are intended to provide the user with a set of recommendations for the best standards of cancer care, based on the findings ofevidence-based medicine. Previous data indicated that prior carboplatin exposure is the primary risk factor for carboplatin-related hypersensitivity reactions among all patients (Navo et al., 2006; Koshiba et al., 2009). It would be worthwhile to evaluate the correlation between other HRD genes and carboplatin hypersensitivity. Incidence and Management of Olaratumab Infusion-Related Reactions. Annals of Oncology (2021) 32 (suppl_5): S407-S446. With a lower carboplatin infusion rate and pre-treatment with anti-allergy drugs, all of these patients were able to tolerate re-treatment with carboplatin, although 48 (78.7%) of these 61 patients developed hypersensitivity again despite the desensitization protocol. doi: 10.1006/gyno.2001.6519, Gadducci, A., Tana, R., Teti, G., Zanca, G., Fanucchi, A., and Genazzani, A. R. (2008). doi: 10.1200/JCO.2003.02.153, Parmar, M. K., Ledermann, J. del Carmen Sancho M, Breslow R, Sloane D, Castells M. Chem Immunol Allergy. Enhancing the feasibility of outpatient daratumumab administration via a split-dosing strategy with initial doses. In the late 1980s, more than a dozen phase I studies analyzed the efficacy of paclitaxel as a single agent. 66, 265267. 18, 615620. Clinical features and management of carboplatin-related hypersensitivity reactions in pediatric low-grade glioma. The drug or food allergy in 735 patients receiving carboplatin-based chemotherapy. This patient developed hypersensitivity reactions during her 23rd cycle of carboplatin administration at a cumulative dose of approximately 14,000 mg. She experienced skin rash, tachycardia, and dyspnea 13 min after starting the infusion. Carboplatin hypersensitivity: does introduction of skin test and desensitization reliably predict and avoid the problem? Most events occurred during chemotherapy. S M S, Naveen NR, Rao GK, Gopan G, Chopra H, Park MN, Alshahrani MM, Jose J, Emran TB, Kim B. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. Allergic and non-allergic ovarian cancer patients treated with carboplatin or carboplatin desensitization presented a similar life expectancy with a non significant advantage for the allergy desensitized patients. Oncol. Cancer. Evaluation of the incidence of carboplatin hypersensitivity in cancer patients. Cancer 19, 12841287. Close monitoring is warranted for patients with a history of drug or food allergy, malignant ascites, or cumulative carboplatin dose >4,000 mg. Strategies for preventing carboplatin-related hypersensitivity include reducing the carboplatin infusion rate and employing desensitization protocols with anti-allergy medications. Prior investigations reported that a history of drug allergies correlates with the incidence of carboplatin-related hypersensitivity reactions (Libra et al., 2003; Sliesoraitis and Chikhale, 2005). Published in 2020 - Ann Oncol (2020) Authors: M.E. The yearly incidence of carboplatin-related hypersensitivity gradually increased from 0.88 in 2006 to 5.42% in 2013 (Table 1), in association with increased use of carboplatin. However, prolonged carboplatin use is associated with an increased incidence of carboplatin-related hypersensitivity reactions (Markman et al., 1999; Wang et al., 2009). doi: 10.1093/annonc/mdt333. Ke. Clinical practice guidance in a modernised format that focuses on visual representation of recommendations for quick and easy reference by practicing clinicians. Careers. The annual incidence of carboplatin-related hypersensitivity reactions gradually increased from 0.88% in 2006 to 5.42% in 2013. Atopic patients are at increased risk for chemotherapy and MoAbs drug allergy and the current patterns of treatment with recurrent and intermittent drug exposures may favor the development of drug allergies. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences. and transmitted securely. WHIPPANY, N.J., Sept. 1, 2017 /PRNewswire/ -- Bayer will present the latest research from across its growing oncology portfolio at the European Society for Medical Oncology (ESMO) 2017 Congress . 15, 780784. A framework to rank genomic alterations as targets for cancer precision medicine.ESCAT scores for genomic alterations with actionable drug matches are now being gradually integrated into ESMO tumour-focused Clinical Practice Guidelines. MeSH Arnall JR, Moore DC, Hill HL, Griffin S, Mueller MK, Lavery LA, Voorhees PM, Usmani SZ. The comparison between other countries and ours about characteristics of the patients receiving carboplatin-based chemotherapy and risk factors of carboplatin-related hypersensitivity reactions. Paclitaxel plus platinum-based chemotherapy vs. conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. are hypersensitivity reactions that are systemic and can be life-threatening (Olsen et al., 2019; Rosell et al., 2017). A three-step method was developed to identify hypersensitivity reactions, including anaphylaxis, in a clinical trial database and could be applied to investigational drugs to improve early detection and monitoring of potential safety concerns, subsequent patient safety management strategies, and potentially programme-wide drug development Cancer 109, 10721078. For more detailed information on the cookies we use, please check our Privacy Policy. J. Gynecol. Drafting of manuscript: Y-HT and W-FC. This site uses cookies. Markman, M. (2007). Sixty-one of these patients were re-challenged with carboplatin following their initial hypersensitivity reaction. ESMO is a Swiss-registered not-for-profit organisation. Gerber, C. van den Hurk, P. Fernndez-Peas, D. Santini, F. Jahn, K. Jordan on behalf of the ESMO Guidelines Committee These ESMO Clinical Practice Guidelines provide recommendations on the . The ESMO 2017 Congress, in partnership with the European Association for Cancer Research (EACR), created an environment where cancer researchers and clinicians came together to collaborate and exchange ideas. A. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences. Our results revealed carboplatin-related hypersensitivity reactions in 1 out of 10 women treated with a carboplatin-containing regimen for ovarian, fallopian tube, or primary peritoneal cancer. Via Ginevra 4, 6900 Lugano - CH Copyright 2023 European Society for Medical Oncology All rights reserved worldwide. Login to your ESMO account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits. No use, distribution or reproduction is permitted which does not comply with these terms. (2016). The ESMO Clinical Practice Guidelines, prepared and reviewed by leading experts and based on the findings of evidence-based medicine, provide you with a set of recommendations to help patients with the best care options. Successful carboplatin desensitization in patients with proven carboplatin allergy. eCollection 2017. Incidence of carboplatin-related hypersensitivity reactions in Japanese patients with gynecologic malignancies. J. Gynecol. Webcasts and presentations from ESMO 2017 can be accessed by ESMO members and event attendees. 105, 8183. Carboplatin hypersensitivity. 10.1016/annonc/annonc687, Anaphylaxis and hypersensitivity in trials of intravenous pertuzumab + trastuzumab (PH IV) or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) for HER2-positive breast cancer (BC), Targeted Therapies and Precision Oncology, Interpreting Oncological Study Publications, Cancer Diagnosis and Treatment Evaluation, Cancer Treatment in Special Clinical Situations, Clinical Pharmacology of Anti-Cancer Agents, Controversies in upper GI oncology: ESMO Open Podcasts, International Prognostic Index Tools for Lymphoma, Anti-Cancer Agents and Biological Therapy, Drug-Drug Interactions with Kinase Inhibitors, PARP inhibition and DNA Damage Response (DDR), Cancer Aetiology, Epidemiology and Prevention, Cancer in Special situations (pregnancy, young, elderly, hereditary), Multikinase Inhibitor-Related Skin Toxicity, Precision Medicine and Validated Biomarkers, ESMO Recommendations in Precision Medicine. Shah et al. 4-step 4-h carboplatin desensitization protocol for patients with gynecological malignancies showing platinum hypersensitivity: a retrospective study. Abstracts, slide sets and webcasts from ESMO 2017 Congress are now available. ESMO Colloquia are innovative sessions within the Congress programme, organised by ESMO and supported by industry, Information about the exhibition and Satellite Symposia, Contact details and welcome message, plus other general information about ESMO 2017. Diagnoses and Management of Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: Reactions to Taxanes and Monoclonal Antibodies. In the US, PH FDC SC can be administered by healthcare professionals in patients (pts) homes. During the study period, our institution applied carboplatin (including carboplatin with cyclophosphamide or paclitaxel) as the front-line chemotherapy for women with ovarian, fallopian tube, and primary peritoneal cancer. Via Ginevra 4, 6900 Lugano - CH Copyright 2023 European Society for Medical Oncology All rights reserved worldwide. For more detailed information on the cookies we use, please check our Privacy Policy.
Shadow Mountain Fairway Cottages Hoa,
Professional Development Epr Bullets,
Reggie Jackson Signed Baseball Card Worth,
City Of Glendale, Wi Permits,
How Many Albums Did Chuck Berry Sell,
Articles E